企業プロフィール
Quoin 株価・ニュース・カタリスト
- ティッカー:
- QNRX
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
5.19 USD (+1.96%)
終値
最終更新: 2026年8月17日
9.16M USD
時価総額
株価変動の要因
Following the latest company update, “Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results”, QNRX closed down 15.9% at $5.09 on Aug 14, 2026. The move occurred in the trading session associated with this earnings update.
企業概要
Rare Dermatology Company
Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing treatments for rare and orphan dermatologic diseases. Its strategy focuses on conditions with limited or no approved therapeutic options and uses topical formulations intended for chronic administration.
QRX003 in Netherton Syndrome
QRX003, also referred to as QYLEKI, is the company's lead topical program for Netherton syndrome. It has received orphan-drug designation in the United States, European Union, and Japan, as well as FDA Fast Track and Rare Pediatric Disease designations.
Peeling Skin Syndrome Expansion
Quoin is expanding QRX003 into peeling skin syndrome, another rare inherited skin disorder. The FDA has cleared the investigational new drug application for this indication, allowing the company to advance a company-sponsored study in the United States and Europe.
QRX009 Rapamycin Platform
QRX009 is a topical rapamycin formulation platform being explored in rare dermatologic conditions including pachyonychia congenita, Gorlin syndrome, and tuberous sclerosis complex. Quoin plans to use investigator-sponsored work and additional regulatory filings to broaden the platform's clinical reach.
今後のカタリスト
- Initiation of a Phase 2/3 study of QRX003 in peeling skin syndrome in the second half of 2026.
- Submission of an additional IND for the QRX009 platform by year-end 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。